Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



康方生物科技(開曼)有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 9926)

CHANGE OF JOINT COMPANY SECRETARY, AUTHORIZED REPRESENTATIVE AND PROCESS AGENT AND

WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES

The board (the "Board") of directors (the "Directors") of Akeso, Inc. (the "Company") has been informed that Ms. CHAN Pung Fei ("Ms. CHAN") who is a joint company secretary of the Company (the "Joint Company Secretary"), has tendered her resignation as the Manager of Corporate Services of Vistra Corporate Services (HK) Limited, which is the external corporate services provider of the Company. As a result of the aforesaid resignation, Ms. CHAN ceased to act as (i) the Joint Company Secretary; (ii) an authorized representative of the Company pursuant to Rule 3.05 of the Rules (the "Listing Rules") Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Stock Exchange") (the "Authorized Representative"); and (iii) an authorized representative of the Company to accept service of process and notices on behalf of the Company in Hong Kong as required under Rule 19.05(2) of the Listing Rules and Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) (the "Process **Agent**") with effect from 14 December 2020. Following the cessation of Ms. CHAN to act as a Joint Company Secretary, the Board is pleased to announce that Ms. SUEN Pui Chun Hannah ("Ms. SUEN") has been appointed as a Joint Company Secretary, the Authorized Representative and the Process Agent with effect from 14 December 2020.

Ms. CHAN has confirmed that she does not have any disagreement with the Board and there are no other matters in relation to her cessation to act in the above positions of the Company that need to be brought to the attention of the shareholders of the Company and the Stock Exchange.

Ms. SUEN is currently a Manager of Corporate Services of Vistra Corporate Services (HK) Limited. She has over thirteen years of experience in providing company secretarial services to numerous private and listed companies. She is currently the company secretary of Peijia Medical Limited, a company listed on the Main Board of the Stock Exchange (stock code: 9996) and the joint company secretary of Ocumension Therapeutics, a company listed on the Main Board of the Stock Exchange (stock code: 1477). Ms. SUEN obtained a Master of Corporate Governance from The Open University of Hong Kong and a Bachelor of Arts (Hons) in Translation and Interpretation from The City University of Hong Kong. She has been an associate member of The Hong Kong Institute of Chartered Secretaries and an associate member of The Chartered Governance Institute in United Kingdom since 2019.

WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES

Reference is made to the waiver (the "Waiver") granted to the Company by the Stock Exchange from strict compliance with the requirements of Rules 3.28 and 8.17 of the Listing Rules in respect of the eligibility of Mr. XI Xiaojie ("Mr. XI") to act as a Joint Company Secretary for a three-year period from the date of the Company's listing on the Main Board of the Stock Exchange (i.e. 24 April 2020) (the "Waiver Period"), on the condition that Mr. XI would be assisted by Ms. CHAN, who possesses the qualifications required under Rule 3.28 of the Listing Rules, during the Waiver Period. Relevant details of the Waiver were disclosed in the section headed "Waivers from Strict Compliance with the Listing Rules and Exemptions from Compliance with the Companies (Winding Up and Miscellaneous Provisions) Ordinance — Waiver in Respect of Joint Companies Secretaries" of the prospectus of the Company dated 14 April 2020.

Given the condition of the Waiver could no longer be fulfilled following the departure of Ms. CHAN, the Company has applied to the Stock Exchange and has already been granted with a new waiver (the "New Waiver") by the Stock Exchange from strict compliance with the requirements under Rules 3.28 and 8.17 of the Listing Rules for the remaining period of the Waiver Period (i.e. from 14 December 2020 to 23 April 2023) (the "New Waiver Period") in relation to the eligibility of Mr. XI to act as a Joint Company Secretary, on the conditions that:-

- (i) Mr. XI will be assisted by Ms. SUEN during the New Waiver Period;
- (ii) the Company shall notify the Stock Exchange at the end of the New Waiver Period for the Stock Exchange to re-visit the situation. The Stock Exchange expects that, after the end of the New Waiver Period, the Company will be able to demonstrate that Mr. XI satisfies the Rules 3.28 and 8.17 of the Listing Rules, having had the benefit of Ms. SUEN's assistance during the New Waiver Period such that a further waiver will not be necessary; and

(iii) the Company will announce the details of the New Waiver, including its reasons and conditions.

The publication of this announcement aims to satisfy condition (iii) set out above.

The Board would like to take this opportunity to express its gratitude to Ms. CHAN for her valuable contributions to the Company during her tenure of service and extend its warm welcome to Ms. SUEN on her new appointment.

By order of the Board

Akeso, Inc.

Dr. XIA Yu

Chairwoman and Executive Director

Hong Kong, 14 December 2020

As at the date of this announcement, the Board comprises Dr. XIA Yu as chairwoman and executive Director; Dr. LI Baiyong, Dr. WANG Zhongmin Maxwell and Mr. XIA Yu (Ph.D.) as executive Directors; Mr. XIE Ronggang and Dr. ZHOU Yi as non-executive Directors; and Dr. ZENG Junwen, Dr. XU Yan and Mr. TAN Bo as independent non-executive Directors.